Argent Capital Management LLC Sells 2,120 Shares of Edwards Lifesciences Co. (NYSE:EW)

Argent Capital Management LLC reduced its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 13.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 14,080 shares of the medical research company’s stock after selling 2,120 shares during the period. Argent Capital Management LLC’s holdings in Edwards Lifesciences were worth $1,042,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in EW. Wellington Management Group LLP increased its stake in shares of Edwards Lifesciences by 86.3% in the third quarter. Wellington Management Group LLP now owns 31,532,725 shares of the medical research company’s stock worth $2,080,845,000 after buying an additional 14,610,123 shares during the period. State Street Corp grew its position in shares of Edwards Lifesciences by 1.0% in the 3rd quarter. State Street Corp now owns 26,265,633 shares of the medical research company’s stock worth $1,733,270,000 after buying an additional 256,538 shares during the period. Geode Capital Management LLC increased its stake in shares of Edwards Lifesciences by 2.2% during the third quarter. Geode Capital Management LLC now owns 13,521,147 shares of the medical research company’s stock valued at $889,050,000 after purchasing an additional 284,918 shares in the last quarter. Fisher Asset Management LLC raised its stake in Edwards Lifesciences by 9.8% during the third quarter. Fisher Asset Management LLC now owns 9,078,311 shares of the medical research company’s stock valued at $599,078,000 after buying an additional 806,705 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Edwards Lifesciences by 1.0% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 6,005,789 shares of the medical research company’s stock worth $396,322,000 after purchasing an additional 61,275 shares during the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Edwards Lifesciences

In other news, insider Larry L. Wood sold 25,000 shares of the business’s stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the completion of the sale, the insider now directly owns 198,526 shares of the company’s stock, valued at $13,084,848.66. The trade was a 11.18 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total value of $327,850.00. Following the transaction, the vice president now directly owns 46,936 shares in the company, valued at $3,077,593.52. This trade represents a 9.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 32,500 shares of company stock valued at $2,160,800 in the last ninety days. Corporate insiders own 1.27% of the company’s stock.

Wall Street Analyst Weigh In

EW has been the subject of a number of recent analyst reports. Bank of America upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $82.00 to $90.00 in a report on Monday, December 16th. Piper Sandler decreased their target price on Edwards Lifesciences from $73.00 to $70.00 and set a “neutral” rating on the stock in a report on Friday, October 25th. Citigroup upped their price target on Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. JPMorgan Chase & Co. lifted their price objective on Edwards Lifesciences from $72.00 to $78.00 and gave the company a “neutral” rating in a research report on Friday, October 25th. Finally, Stifel Nicolaus raised their target price on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the stock a “hold” rating in a research note on Thursday, December 5th. One research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $78.48.

Edwards Lifesciences Stock Down 1.1 %

Shares of Edwards Lifesciences stock opened at $70.29 on Thursday. The company has a market cap of $41.46 billion, a P/E ratio of 10.14, a PEG ratio of 3.77 and a beta of 1.11. The firm has a fifty day moving average of $71.82 and a two-hundred day moving average of $71.62. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $96.12.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.67. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The company had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.57 billion. During the same period last year, the firm earned $0.59 EPS. The company’s revenue for the quarter was up 8.9% on a year-over-year basis. On average, analysts forecast that Edwards Lifesciences Co. will post 2.56 earnings per share for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.